Oxford Biomedica Provides Update on CDMO Services Including New Commercial Agreement

20 March 2024

Oxford, UK – 20, March, 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today provides an update on its CDMO services activity. 

New and expanded contracts highlight commercial momentum across all viral vector types 

OXB now working on multiple late-stage programmes with its portfolio of client programmes  progressing to later stage work

Year to date, Oxford Biomedica has experienced consistently strong demand for its CDMO services  across all key viral vector types, with its portfolio of client programmes transitioning towards later stage  work. As a result of commercial developments set out below, OXB is now working on three late-stage  programmes. 

Recently, the Company signed a contract with a new undisclosed US-based biotechnology company  for the manufacture of lentiviral vectors as the client prepares for the commercial launch of its CAR-T  programme targeting multiple myeloma. Manufacturing will take place in Oxbox, the Company’s Oxford based manufacturing facility. 

Alongside this, Oxford Biomedica has signed two new programmes with existing clinical-stage clients for projects including Process Development and GMP manufacturing. 

Furthermore, the Company has signed a new agreement with a US-based client specialising in cardiac  gene therapy for the tech transfer, optimisation and manufacture of an adeno-associated virus-based process (AAV). 

Under the terms of these agreements, Oxford Biomedica will receive payments related to the  development and manufacturing of viral vectors for use in clinical trials in addition to certain  development and regulatory milestone payments. These payments will support the Company in  achieving its medium-term financial guidance announced on 5 March 2024

Dr Sébastien Ribault, Chief Commercial Officer of Oxford Biomedica, commented: “The signing of a late-stage programme, alongside the continued expansion of existing agreements since the start of 2024, demonstrates clients’ confidence in OXB’s ability to deliver process development and GMP manufacturing services. Our Business Development team continues to experience strong demand for process characterisation, validation, and process performance qualification (PPQ) work, showcasing the high quality and reliability of our services. This demand is in line with our forecasts across all key vectors and geographies, validating our growth strategy. We remain confident about our future prospects as the leading global pure-play CDMO in cell and gene therapy and our ability to continue building our client portfolio.” 





Oxford Biomedica plc:

Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 1865 509 737 / E: ir@oxb.com

ICR Consilium:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

Mary-Jane Elliott / Matthew Neal / Davide Salvi

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy contract development and manufacturing organisation (CDMO) with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenoviral vectors, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.